A Phase 1 interventional study of Guselkumab and Risankizumab in Arthritis, Psoriatic and Healthy, sponsored by Janssen Research & Development, LLC. Terminated at 1 site in Austria. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-26.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing guselkumab in Arthritis, Psoriatic — 5 open to participants now, 8 under way, 3 of them phase 3. guselkumab · Arthritis, Psoriatic.
Among the 14 studies testing guselkumab in Arthritis, Psoriatic, this one is the 13th largest by enrollment, is one of 4 that started in 2021, is the only one in phase 1, and was the 8th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.
Browse Arthritis, Psoriatic studies →5 of the 14 studies testing guselkumab in Arthritis, Psoriatic are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
NYU Langone Health · Sites in United States
Ages 18+
Johnson & Johnson Private Limited · Sites in India
Ages 18+
University of California, San Diego · Sites in United States
Janssen Research & Development, LLC · Sites in United States, Argentina, Australia and 15 more countries
Ages 3+
By country, each count listing its studies:
guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 145 across 336 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 173 across the 14 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 14 have an industry lead sponsor. The 6 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
37 studies in Arthritis, Psoriatic by Johnson & Johnson: 5 open now, 13 under way, 5 of them phase 3. Of 23 finished, 13 (57%) have results posted.
Among the 37 studies in Arthritis, Psoriatic by Johnson & Johnson, this one is the 24th largest by enrollment of the 25 interventional ones that give a count, is one of 7 that started in 2021, is one of 2 in phase 1, and was the 28th registered.
Johnson & Johnson’s Arthritis, Psoriatic studies by the year they started, since 2002.
4 of the studies testing guselkumab in Arthritis, Psoriatic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04929210Janssen Research & Development, LLCA Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease | 2027-04-01 |
| NCT07141004Johnson & Johnson Private LimitedA Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA) | 2027-06-05 |
| NCT07654751Janssen Research & Development, LLCA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | 2027-08-31 |
| NCT06586281University of California, San DiegoElucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 14 studies testing guselkumab in Arthritis, Psoriatic, from their registry updates:
Among Johnson & Johnson’s 37 in Arthritis, Psoriatic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the tissue distribution of guselkumab and risankizumab in healthy participants (Part 1) and psoriatic arthritis (PsA) participants (Part 2 and Part 3).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part 1:
Parts 2 and 3:
Exclusion Criteria:
Part 1:
Parts 2 and 3:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy participants will receive a single co-administered dose of risankizumab and guselkumab subcutaneously (SC) on Day 1.
Drug: Guselkumab · Drug: Risankizumab
Participants with PsA will receive a single co-administered dose of risankizumab and guselkumab SC on Day 1 and Day 29.
Drug: Guselkumab · Drug: Risankizumab
Participants with PsA will receive a single dose of either risankizumab or guselkumab SC on Day 1 and Day 29.
Drug: Guselkumab · Drug: Risankizumab
Guselkumab will be administered subcutaneously.
Also known as: Tremfya, CNTO1959
Risankizumab will be administered subcutaneously.
Also known as: Skyrizi
Parts 1 , 2 and 3: Skin Tissue versus Serum Concentration Ratio
Skin tissue versus serum concentration ratio will be summarized.
Time frame: Up to Week 12
Part 1: Colon Tissue versus Serum Concentration Ratio
Colon tissue versus serum concentration ratio will be summarized.
Time frame: Up to Week 8
Parts 2 and 3: Colon Tissue versus Serum Concentration Ratio
Colon tissue versus serum concentration ratio will be summarized.
Time frame: Up to Week 4
Parts 2 and 3: Synovial Tissue versus Serum Concentration Ratio
Synovial tissue versus serum concentration ratio will be summarized.
Time frame: Up to Week 12
Parts 1, 2 and 3: Maximum Observed Serum Concentration (Cmax) of Guselkumab and Risankizumab
Cmax is defined as maximum observed serum concentration.
Time frame: Part 1: Up to Week 16, Parts 2 and 3: Up to Week 24
Parts 1, 2 and 3: Time to Reach Maximum Observed Serum Concentration (Tmax) of Guselkumab and Risankizumab
Tmax is defined as time to reach maximum observed serum concentration.
Time frame: Part 1: Up to Week 16, Parts 2 and 3: Up to Week 24
Parts 1, 2 and 3: Area Under the Serum Concentration Versus Time Curve from Time Zero to the Time Corresponding to the Last Quantifiable Concentration (AUC[0-last]) of Guselkumab and Risankizumab
AUC(0-last) is defined as area under the serum concentration versus time curve from time zero to the time corresponding to the last quantifiable concentration.
Time frame: Part 1: Up to Week 16, Parts 2 and 3: Up to Week 24
Parts 1, 2 and 3: Area Under the Plasma Concentration-time Curve from Time 0 to infinity (AUC[0 - Infinity]) of Guselkumab and Risankizumab
AUC(0-infinity) is defined as area under the plasma concentration-time curve from time 0 to infinity with extrapolation of the terminal phase.
Time frame: Part 1: Up to Week 16, Parts 2 and 3: Up to Week 24
Parts 1, 2 and 3: Terminal Half-life (T1/2)
T1/2 is defined as terminal half-life.
Time frame: Part 1: Up to Week 16, Parts 2 and 3: Up to Week 24
Parts 1, 2 and 3: Apparent Total Clearance (CL/F) of Guselkumab and Risankizumab
CL/F is defined as apparent total systemic clearance after extravascular administration.
Time frame: Part 1: Up to Week 16, Parts 2 and 3: Up to Week 24
Parts 1, 2 and 3: Apparent Volume of Distribution Based on Terminal Phase (Vz/F) of Guselkumab and Risankizumab
Vz/F is defined as apparent volume of distribution based on terminal phase after extravascular administration.
Time frame: Part 1: Up to Week 16, Parts 2 and 3: Up to Week 24
Parts 1, 2 and 3: Number of Participants with Antibodies to Guselkumab and Risankizumab
The detection and characterization of antibodies to guselkumab and risankizumab will be performed using a validated assay method.
Time frame: Part 1: Up to Week 16, Parts 2 and 3: Up to Week 24
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
No publications or documents are linked to this record.
Ran from Nov 2021 to primary completion in Jul 2022, 7 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Guselkumab · Risankizumab
Janssen Research & Development, LLC →